PROGRAMME AT A GLANCE

Size: px
Start display at page:

Download "PROGRAMME AT A GLANCE"

Transcription

1 PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver Transplant Theme : Liver Transplant APASL- AASLD Clinical Research Methodology Workshop Day to Day Challenges 08:30 10:30 08:00-09:30 Session 1: Regenerative Session 1:LDLT in difficult Medicine: Cells to Organsituations 1 08:05-10:10 Session 1: Observational Studies 10:50-11:15 09:30-10:30 Session 2: Immunosuppression for Liver Transplantation 10:10-10:30 11:15-12:55 Session 1: Regenerative Medicine: Cells to Organ- 2 10:30-11:00 10:30-12:35 Session 2: Experimental studies 14-Mar-18 13:00-14:30 11:00-12:30 Session 3: Transplant Grand Rounds-Cases [mentor and mentee] 12:35-13:35 Session 3: Plenary Session 14:30-16:45 Session 2: Advanced tools of cytoanalysis 12:30-13:30 Session 4: Post liver transplant radiology and pathology 13:35-14:20 16:45-17:00 13:30-14:30 14:20-16:20 Session 4: Break out Room A

2 Session 5: Perioperative management of liver 17:00-18:25 transplant patient Session 3: Lipid, Bile acids and iron trafficking in homeostatic and disease physiology 16:00-16:15 14:20-16:20 Session 4: Break out Room A Editor Forum 16:30-17:30 What do the Editors look for in manuscript for decision making? Main PG course Workshop: Experimental models of liver 15 th March, 08:00-09:45 Session 1: Viral Hepatitis: Difficult Treatment Decisions 09:45-11:15 Session 2: Alcoholic Liver Disease and Non-alcoholic fatty Liver Disease 08:00-10:10 Workshop Session 1: 11:00-11:20 11:20-12:10 Session 3: Alcoholic Liver Disease 12:10-13:30 Session 4: Challenges in Hepatology 11:20-13:20 Workshop Session 2: 15th March, 13:30-14:30 symposia Session 5: Prescriptions in Liver Diseases 15:45-17:00 Session 6: Complications of Cirrhosis Workshop Session 3: 16:00-17:00 Workshop Session 4: Session 7: Liver Failure CEVHAP Symposium: Partnerships in Action Faculty Dinner

3 16 th March, Pediatric hepatology Critical Care Heptology Oral papers Oral papers Oral papers 08:00-09:40 Session 1: Viral Hepatitis B- HepatitisSession: 1 APASL-ISHEN Session 1: APASL -IAC new challenges session: Hepatic Encephalopathy-Hepatic Encephalopathy in Cirrhosis SYMPOSIUM Session 2 : Cholestatic Liver 09:45-10:15 Session 2: Viral Hepatitis C- Challenges Disease - Pathophysiology of in Treatment of HCV Infection cholestasis and cholestatic liver 08:00-10:00 Session 1: Cholestatic disorders of childhood Session 1: Kidney Dysfunction in Liver Failure Session 2: Nutrition and Coagulation in Liver Failure 10:45-11:55 Session 3: NAFLD- NAFLD as a Systemic Disease 10:45-11:50 Session 3 : Liver Failure 10:15-10:45 + Poster rounds 10:30-12:10 Session 2: Portal Session 2: Advances in Hypertension, Pediatric Liver Diseases coagulation and Variceal Bleed- Screening, Session 3 :Septic shock in Liver prophylaxis and Failure management of bleeding in Liver 16th March, 11:55-13:15 11: Session 4: Liver Fibrosis- Pathogenesis Session 4: Musculoskeletal of liver fibrosis disorders in chronic liver disease 12: Session 3: Hepatocellular Session 3: Non-cirrhotic carcinoma -PathogenesisPortal hypertension and diagnosis of HCC 12: 00-13:15 Session 4: Brain and Heart in Sepsis in Liver Failure Plenary Presentations Young Investigator award presentations (Basic) Session 4: APASL- AASLD Symposium on Alcoholic Liver Disease Oral Paper Poster round + Symposia Session 5: Pulmonary Dysfunction in liver failure 16:50-17:55 Session 5: Alcoholic liver disease- Global Alliance on Alcoholic Liver Disease (GLAD) 17:15-18:15 Session 5: Drug Forum: 15:30-16:30 15:45-16:30 Session 4: Metabolic Live Session 6: Case scenarios in critical care hepatology-1 16:30-16:50 Coffee break+ Poster rounds 17:00-17:45 Session 5:Cholestatic Session 5: Liver Session 7 : Case scenarios in Liver Disease - Diagnosis Transplantation in Critical care Hepatology and Management of childhood Cholestatic liver 18:15-19:15 Evening Symposium Dinner 20:30- Onwards

4 17 th March, Liver Pathology Symposium and Radiology Session Nutrition in liver APASLINASL Symposium Hepatovirology Oral papers Oral papers Oral papers 08:30-09:30 Session 1: Alcoholic liver disease- Session 1: Hepatic Session 1: Liver Patholog Session 1: Nutritional Global Alliance on Alcoholic Liver regenerative medicine- Nontransplant approaches in a Liver Pathology Update/ Advances in Assessment in cirrhosis Disease (GLAD) 08:00-10:00hrs failing liver Session 1: APASL-EASL Symposium : What I do 09:30-10:30 09:10-10:20 not know about chronic Session 2: Hepatic Session 2: Liver fibrosis Session 2 : Nutritional hepatitis B virus infectio Encephalopathy- Hepatic interventions in Cirrhotic with Session 2: Viral hepatitis C- HCV Encephalopathy in Acute Liver Failure replication and co-infections Liver failure and Acute on Chronic Liver Failure 10:15-10:45 + Poster rounds 10:45-12:10 11:00-12:00 Session 3: NAFLD- Pathogenesis, Session 3: Autoimmune Live Session 3: Liver tumors- Session 3:Nutrition in Liver Epidemiology and Natural History of Disorders- Pathogenesis and update Failure NAFLD Diagnosis of Autoimmune Liver Disorders Session 4: Liver immunology and inflammation 11:15:-12:15 12:00-13:00 12: 00-13:15 Session: Hepatocellular Session 4: Liver transplan APASL INASL Symposium carcinoma -Staging and pathology-1 Management of HCC Session 4: Mixed and rare Liver Tumors-Diagnosis and Management 17th March, + Symposium 14:30-15:00 Plenary Presentations Young Investigator award presentations (Clinical) 14:30-15:15 Session 1: Liver imaging Session 1: Hepato-Virology Symposium: Viral Hepatitis Testing: way forward 15:00-16:30 Plenary Presentations (Basic) State of the art(world Gastroenterology Organization ) lecture 15:15-16:00 Session 2: Interventional Radiology in Portal Hypertension 16:30-17:00 Coffee break+ Poster rounds

5 18 th March, Session 5: Viral hepatitis B-Newer therapies for cure of Hepatitis B Session 6: Portal Hypertension, Coagulation and Variceal Bleed- 16:30-17:15 Session 3: Intervention Radiology in Liver Tumours 16:30-18:00 Session 2: Viral infections in Solid organ transplants Coagulation, thrombosis and vascular Liver Diseases 17:15-18:00 Session 4: Intervention Radiology in post transplant and biliary system 18:15-19:15 Evening Symposium APASL-INASL Symposium Endoscopy in liver : Theme-Challanges for advanced endoscopy in liver Oral papers Oral papers Oral papers Session 1: Viral hepatitis B- HBV in special situations 08:00-10:00 08:00-10:15 Session 1: Portal Session 1: Alcohol, Session 1: Liver Clinic (10 Session 1: GI endoscopy in Hypertension, Coagulation Obesity and Liver Cancer and Variceal Bleed- Challenges in coagulation an vascular of liver cases can be selected) patients with liver Session 2: Autoimmune liver DisordeSession 2: Alcoholic Liver Management of Autoimmune Liver Disease- Management of Disorders Severe Alcoholic Hepatitis Session: Iron in Liver 18 th March, Session 3: Hepatocellular carcinoma - Novel Therapeutic targets for HCC 11:15-11:45 12:00-13:00 Session 4: Drug Induced Liver Injury- Spectrum of DILI 10:15-10:45 Session 2: Biliary interventions Session 2: INASL Clinical in portal hypertension Practice Guidelines 10:15-12:00 12: 15-13:15 Session 3: Bile acids and Session 3: Endoscopic Session 3: APASL-INASL Liver Aisease management of obesity in liver CPC [Case from PGI] 11:45-13:00 Session 3: Hepatic regenerative medicine- Cell therapies in Liver Diseases Session 4: Frontiers in Liver Disease Symposium + Poster Rounds Session 4: EUS in portal hypertension- why, when and how?

Autoimmune Hepatitis Events Easl

Autoimmune Hepatitis Events Easl Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

Life After SVR for Cirrhotic HCV

Life After SVR for Cirrhotic HCV Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data

More information

Clinical Trials & Endpoints in NASH Cirrhosis

Clinical Trials & Endpoints in NASH Cirrhosis Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com

More information

4th UpDate on Hepatology

4th UpDate on Hepatology 4th UpDate on Hepatology Course Bucharest 2017, Romania 6 th - 7 th April 2017 Bucharest - Crowne Plaza Hotel Hepatology 2017 A panoramic view" Liana GHEORGHE Course Directors Ioan SPOREA Anca TRIFAN 4

More information

During the course of the 12 month fellowship, candidates will attend at least one international liver meeting (generally AASLD).

During the course of the 12 month fellowship, candidates will attend at least one international liver meeting (generally AASLD). Hepatology and Liver Transplantation fellowship Length: 1 year Number of positions: 2 Type of fellowship: Clinical and Research Fellowship Director: Dr. Deschenes McGill University Health Centre Fellowship

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt

More information

Overall Goals and Objectives for Transplant Hepatology EPAs:

Overall Goals and Objectives for Transplant Hepatology EPAs: Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty

More information

Dr. Siddharth Srivastava

Dr. Siddharth Srivastava Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.

More information

HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS

HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A Roadmap For Hepatology Research In Europe: An Overview For Policy Makers Liver diseases are extremely costly

More information

MINI PROGRAMME SEE YOU NEXT YEAR IN LONDON APRIL 2020

MINI PROGRAMME   SEE YOU NEXT YEAR IN LONDON APRIL 2020 MINI PROGRAMME WWW.ILC-CONGRESS.EU SEE YOU NEXT YEAR IN LONDON 15-19 APRIL 2020 Registration area Foyer D Membership fast-track, self-registration lanes, help desk, accommodation desk, congress material,

More information

Hepatitis C Update on New Treatments

Hepatitis C Update on New Treatments Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes

More information

Preliminary Program Outline

Preliminary Program Outline Saturday, June 2, 2018 1:00 pm 5:30 pm Pre-Meeting Symposia Advanced Immunology Basic Science for the Clinician The Immunology of Kidney Transplantation Transplant Center QAPI and Advanced Leadership:

More information

CAPGAN th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India

CAPGAN th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India CAPGAN2015 14 th Scientific Meeting of Commonwealth Association of Paediatric, Gastroenterology and Nutrition 2-4 October 2015 : New Delhi, India ABSTRACT FORM Abstract Category: Oral Poster 1. GASTROENTEROLOGY

More information

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE

More information

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Gastroenterology. Certification Examination Blueprint. Purpose of the exam Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist

More information

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob: Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).

More information

Day-at-a-Glance. Saturday, June 2, 2018

Day-at-a-Glance. Saturday, June 2, 2018 Saturday, June 2, 2018 1:00 pm 5:30 pm Pre-Meeting Symposia (Additional Fee) Advanced Immunology Basic Science for the Clinician The Immunology of Kidney Transplantation Transplant Center QAPI and Advanced

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

The 10th Congress of the Jordanian Society of Gastroenterology & Hepatology

The 10th Congress of the Jordanian Society of Gastroenterology & Hepatology 2014 The 10th Congress of the Jordanian Society of Gastroenterology & Hepatology Organized by: The Jordanian Society of Gastroenterology & Hepatology In Collaboration with: The Pan Arab Society of Gastroenterology

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

HCV care after cure. This program is supported by educational grants from

HCV care after cure. This program is supported by educational grants from HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico

More information

Western Health Specialist Clinics Access & Referral Guidelines

Western Health Specialist Clinics Access & Referral Guidelines Gastroenterology Specialist Clinics at Western Health: Western Health provides the following Specialist Clinics for patients who require assessment and management of Gastroenterology / Hepatology conditions.

More information

2017 Canadian Association of Gastroenterology Educational Needs Assessment Report

2017 Canadian Association of Gastroenterology Educational Needs Assessment Report 2017 Canadian Association of Gastroenterology Educational Needs Assessment Report Kevin A. Waschke MD., CM., FRCPC, FASGE VP Education Affairs, Canadian Association of Gastroenterology Karen Sparkes BASc

More information

FRIDAY, MARCH 9 SUNDAY, MARCH

FRIDAY, MARCH 9 SUNDAY, MARCH 33RD A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 9 SUNDAY, MARCH 11, 2018 Pre-Conference: Friday, March 9, 2018 Main Conference: Saturday, March 10-11, 2018 Estancia La Jolla Course

More information

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis

More information

Management of Hepatitis B - Information for primary care providers

Management of Hepatitis B - Information for primary care providers Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines

More information

The Role of Liver Societies in the Global Viral Hepatitis Response

The Role of Liver Societies in the Global Viral Hepatitis Response The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

HEPATOCELLULAR CARCINOMA: AN OVERVIEW HEPATOCELLULAR CARCINOMA: AN OVERVIEW John K. Olynyk Head, Department of Gastroenterology & Hepatology Fiona Stanley Fremantle Hospital Group Dean of Research, Edith Cowan University RISING MORTALITY OF

More information

5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition

5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition 5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition SIXTH DRAFT OF THE PROGRAM AUGUST 28, 2014 Wednesday, October 5, 2016 08:00-16:30 Post Graduate course (To be developed by the

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

NEURO- GASTRO- ENTEROLOGY & MOTILITY OESO- PHAGUS LOGY. Room A Room B Room C Room E1 Room E2 Room M Room N1 Room N2 Room L8 Room 1.

NEURO- GASTRO- ENTEROLOGY & MOTILITY OESO- PHAGUS LOGY. Room A Room B Room C Room E1 Room E2 Room M Room N1 Room N2 Room L8 Room 1. ONCO ENTERO RADIO & SATURDAY SUNDAY MONDAY TUESDAY WEDNESDAY Saturday, October 15, 2016 Room A Room B Room C Room E1 09:00-10:30 Peptic ulcer : Still important for gastroenterologists 11:00-13:00 Video

More information

Hepatology for the Nonhepatologist

Hepatology for the Nonhepatologist Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

The Role of Liver Societies in the Global Viral Hepatitis Response

The Role of Liver Societies in the Global Viral Hepatitis Response The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

Liver disease in 2017: challenges and opportunities

Liver disease in 2017: challenges and opportunities Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National

More information

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,

More information

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Liver Transplantation Evaluation: Objectives

Liver Transplantation Evaluation: Objectives Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

SCIENTIFIC PROGRAMME

SCIENTIFIC PROGRAMME SCIENTIFIC PROGRAMME Tuesday, May 25 th 2017 08.30-09.30 ORAL PRESENTATIONS (HALL 1) Chairpersons : G. Baltagiannis, E. Vezali 08.30-09.30 Oral Presentations HALL 2) Chairpersons: E. Dimou, O. Giouleme

More information

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint

GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments

More information

ELPA S VISION OF SCREENING

ELPA S VISION OF SCREENING ELPA S VISION OF SCREENING By Nadine Piorkowsky President of the European Liver Patients Association, Budapest, 18-19 March 2010 ELPA s network The Patient s View a viral time bomb: Up to 9 out of 10 chronic

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

Hepatology For The Nonhepatologist

Hepatology For The Nonhepatologist Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able

More information

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Liver Failure. The most severe clinical consequence of liver disease is liver failure:

Liver Failure. The most severe clinical consequence of liver disease is liver failure: Liver diseases I The major primary diseases of the liver are: - Viral hepatitis, - Nonalcoholic fatty liver disease (NAFLD), - Alcoholic liver disease, - Hepatocellular carcinoma (HCC) Hepatic damage also

More information

Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.

More information

LIVER DISEASE WRAP-UP

LIVER DISEASE WRAP-UP 20th Annual LIVER DISEASE WRAP-UP An Update on Advances in Clinical Hepatology An update on advances in clinical hepatology presented at the 2017 AASLD Meeting for Practicing Internists, Gastroenterologists,

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

Management of Patients with Chronic Hepatitis B: The Alaska Experience

Management of Patients with Chronic Hepatitis B: The Alaska Experience Management of Patients with Chronic Hepatitis B: The Alaska Experience Brian J McMahon, MACP, FAASLD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Disclosures I have no conflicts

More information

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

34TH. New Treatments in Chronic Liver Disease. MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla La Jolla, California

34TH. New Treatments in Chronic Liver Disease. MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla La Jolla, California 34TH A N N U A L New Treatments in Chronic Liver Disease MAIN CONFERENCE: MARCH 9 10, 2019 Pre-Conference: March 8, 2019 Estancia La Jolla Course Introduction Course Overview This CME conference will review

More information

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging for further reference: Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach Neil Theise, MD. Depts of Pathology

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

Tumor incidence varies significantly, depending on geographical location.

Tumor incidence varies significantly, depending on geographical location. Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.

More information

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT. Investigations before OLT, Immunosuppression and rejection, Follow up after OLT andrea.degottardi@insel.ch When is liver transplantation indicated? When is liver transplantation indicated? Frequent: CIRRHOSIS

More information

The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom

The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom The Sheila Sherlock Royal Free Hepatology Postgraduate Course 2019 Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom *Includes histopathology within talk # Includes radiology

More information

Supplementary Digital Content

Supplementary Digital Content Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy

More information

Hepatitis C Policy Discussion

Hepatitis C Policy Discussion Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

PREVALENCE OF NAFLD & NASH

PREVALENCE OF NAFLD & NASH - - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated

More information

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015 1 A Brief Introduction to the Liver Sessions 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology Sarajevo, 6 th -7 th November 2015 Stefan Hübscher, Institute of Immunology & Immunotherapy,

More information

NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF

NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF Royal Armouries International, Leeds 17 June 2015 17 th Annual Conference of

More information

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams

More information

STOP Hepatocellular Carcinoma

STOP Hepatocellular Carcinoma STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

The subject is composed from theoretical lectures and clinical practicals.

The subject is composed from theoretical lectures and clinical practicals. Published on Second Faculty of Medicine, Charles University ( https://www.lf2.cuni.cz) Internal Medicine I Submitted by Marie Havlová on 28. August 2014-0:00 Syllabus of Internal Medicine I The subject

More information

Liver Disease in Cystic Fibrosis

Liver Disease in Cystic Fibrosis Liver Disease in Cystic Fibrosis Basic Overview Clinical Aspects Management What Is Cystic Fibrosis? Autosomal recessive disease W-1:3000, H-1:10,000, AA-1:15,000 Mutations of CFTR defective Cl - transport

More information

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%

More information

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment

More information

THURSDAY, SEPTEMBER 20 TH

THURSDAY, SEPTEMBER 20 TH SCIENTIFIC PROGRAM THURSDAY, SEPTEMBER 20 TH 08:30 08:50 hrs. Welcoming address to the XXIV ALEH CONGRESS 2018 Dr. Fernando Contreras (ALEH President) and Dr. Marlene Perez (Congress President) 08:50 09:00

More information

HCC: Is it an oncological disease? - No

HCC: Is it an oncological disease? - No June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -

More information

Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology

Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology Faculty representative: David L. Burns, MD, CNSP Resident representative: Tom Castiglione, MD Revision date: March 6, 2006

More information

Learning Objectives. After attending this presentation, participants will be able to:

Learning Objectives. After attending this presentation, participants will be able to: Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation

More information

The place of bariatric surgery in NASH: can we extend the indications? - No

The place of bariatric surgery in NASH: can we extend the indications? - No The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the

More information

FRIDAY, MARCH 31 SUNDAY, APRIL

FRIDAY, MARCH 31 SUNDAY, APRIL 32ND A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 31 SUNDAY, APRIL 2, 2017 Pre-Conference: Friday, March 31, 2017 Main Conference: Saturday, April 1-2, 2017 Estancia La Jolla La Jolla,

More information

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death

More information

Hepatocellular carcinoma in Sri Lanka - where do we stand?

Hepatocellular carcinoma in Sri Lanka - where do we stand? SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior

More information

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare 6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,

More information

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence

More information

New York State HCV Provider Webinar Series. Side Effects of Therapy

New York State HCV Provider Webinar Series. Side Effects of Therapy New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related

More information

Gastrointestinal System: Accessory Organ Disorders

Gastrointestinal System: Accessory Organ Disorders Gastrointestinal System: Accessory Organ Disorders Mary DeLetter, PhD, RN Associate Professor Dept. of Baccalaureate and Graduate Nursing Eastern Kentucky University Disorders of Accessory Organs Portal

More information

Changing epidemiology of HCC in Italy

Changing epidemiology of HCC in Italy Changing epidemiology of HCC in Italy G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche-Trapianto di Fegato Università Politecnica delle Marche, Ancona Worldwide estimated new PLC

More information